期刊文献+

甲磺酸伊马替尼的合成 被引量:1

Synthesis of imatinib mesylate
下载PDF
导出
摘要 目的研究和改进甲磺酸伊马替尼的合成工艺。方法以3-乙酰吡啶、4-甲基-3-硝基苯胺等为原料,经过环合、氯化、还原、缩合,进而与甲磺酸成盐得到甲磺酸伊马替尼。结果目标化合物经质谱、核磁共振氢谱等确证,总收率45.7%。结论该合成方法简便,成本低,适合工业化生产。 Objective To research and improve the synthesis of imatinib mesylate.Methods Using 3-acetylpyridine and 4-methyl-3-nitroaniline as raw matrials,imatinib mesylate was synthesized by cyclization,chlorination,reduction,condensation and salification with methane sulfonic acid.Results The structure of target compound was identified by MS and 1H-NMR.The overall yield was 45.7%.Conclusion The simple cost-saving synthetic method can be used in the industrial preparation.
出处 《济宁医学院学报》 2012年第2期103-105,共3页 Journal of Jining Medical University
基金 济宁医学院2008年青年基金项目
关键词 伊马替尼 合成 酪氨酸激酶抑制剂 Imatinib Synthesis Tyrosine kinases inhibitor
  • 相关文献

参考文献9

  • 1Huang AL, Liu X, Lior Z, et al. Novel process for preparing Imatinib[P]. US: 2006149061,2006-07-06.
  • 2Paul WM,Werne RB,Jose FB. Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases[J]. Bioorg Med Chem Lett, 2004,14 : 5793-5797.
  • 3Zimmermann J. Pyrimidine derivatives and processes for the preparation thereof[P]. US: 5521184,1996-05-28.
  • 4李铭东,李东,吉民.甲磺酸伊马替尼的合成[J].中国药学杂志,2008,43(3):228-229. 被引量:19
  • 5Dusza JP, Albright JD. Substituted pyrazolo (1,5-a) pyrimi dines and their use as anxiolytic agents[P]. US: 4281000, 1981-07-28.
  • 6陈敖,黄荷香,宋帅娟,陈小琴.甲磺酸伊马替尼的合成[J].精细与专用化学品,2007,15(8):23-25. 被引量:11
  • 7孙继铨,尚志强,陈华.治疗慢性粒细胞白血病伊马替尼中间体的制备方法[P].CN:101701015,2010-0505.
  • 8Kompella AK, Thungathurthi SR, Bhujanga Rao AKS, et al. Novel polymorphic form of Imatinib mesylate and a process for its preparation[P]. WO: 2005077933,2005-08- 25.
  • 9Kompella AK,Bhujanga Rao AKS, Sreenivas R, et al. Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl ki- nase[P]. WO:2006027795,2006 03-16.

二级参考文献12

  • 1李肃,王椿.慢性粒细胞白血病的治疗选择[J].世界临床药物,2005,26(8):464-466. 被引量:3
  • 2[2]Kompella Amala,Bhujanga Rao Adibhatla Kali Sa,et al.Process for the preparation of the anti-cancer drug Iimatinib and its analoguse[P].WO 2004/108699
  • 3[3]Loiseleur Olivier,Kaufmann Daniel,et al.N-Phenyl-2-pyrimidineamine derivatives[P].WO 03/066613
  • 4[4]朱淬励.药物合成反应[M].北京:化学工业出版社,1987
  • 5[5]Kim Dong-Yeon,Kim Jae-Gun,et al.N-Phenyl-2-pyrimidine amine derivatives and process for the preparation thereof[P].WO 2004/099187
  • 6[6]Amala Kompella,Srinivasa Rao Thungathurthi,et al.Novel polymorphic form of Imatinib mesylate and a process for its preparation[P].WO2005077933
  • 7JURG Z, WALLBACH. Pyrimidine derivatives and processes for the preparation thereof: US,5521184[ P]. 1996-05-28.
  • 8JOHN P D, JAY D A. Substituted pyrazolo (1,5-A) pyrimidines and their use as anxiolytic agents: US,004281000 [ P]. 1982-07-28.
  • 9PAUL W M, WERNER B, JOSEF B. Urea derivatives of ST1571 as inhibitors of Bcr-Abl and PDGFR kinases [ J ]. Bioorg Med Chem Lett,2004, 14 : 5793-5797.
  • 10JURG Z. Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for facture and its use: WO,9903854[ P]. 1999-01-28.

共引文献23

同被引文献14

  • 1王晨.甲磺酸伊马替尼抗肿瘤作用的研究[J].天津药学,2005,17(4):63-66. 被引量:3
  • 2郑斌,危晴岚,刘茂柏.甲磺酸伊马替尼临床研究概况[J].海峡药学,2006,18(6):78-80. 被引量:12
  • 3陈敖,黄荷香,宋帅娟,陈小琴.甲磺酸伊马替尼的合成[J].精细与专用化学品,2007,15(8):23-25. 被引量:11
  • 4Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia[J].Clin Cancer Res,2002,8 ( 5 ) : 935-942.
  • 5Giordani A, Kobel W, Gally HU. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process[J]. EurJ PharmSci,2011,43 ( 1-2): 1-15.
  • 6Raman NVVSS, Prasad AVSS, Reddy KR. Strategies for the identification, control and determination ofgenotoxic impurities in drug suhstance:A pharmaceutical industryperspective [J].J Pharm Biomed Anal,2011,55 ( 4 ) : 662-667.
  • 7Kakadiya PR, Reddy BP, Singh V, et al.Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir active pharmaceutical ingredients by LC/MS/MS using electrospray ionization[J].J Pharm Biomed Anal,2011,55 ( 2 ): 379-384.
  • 8Montesano MA, Whitehead JRD, Jayatilaka NK, et al. Measurement of methyl methanesulfonate in humaan plasma and breast milk samples using high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry[J].J Pharm Biomed Anal, 2010,52 ( 2 ) : 260-264.
  • 9An V, Sun M, Bai L, et al. A practical derivatization LC/MS approach for determination of tace level alkyl sulfonates and dialkyl sulfates genotoxic impurities in drug substances [J].J Pharm Biomed Anal, 2008,48 ( 3 ): 1006-1010.
  • 10Oostendorp RL, Beijnen JH, Schellensi HM, et al. Determination of imatinib mesylate and its main metabolite (cgp74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography[J].Biomed Chromatngr Published Online, 2007,27 ( 3 ) : 34-36.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部